CNS Pharmaceuticals Company Presentation

CNS pharmaceuticals 17 Pipeline: WP1244. • Licensed from The University of Texas MD Anderson Cancer Center • Developed in the Department of Experimental Therapeutics as a collaborative effort with the Neuro-Oncology Department and Pharmaceutical Development Center. • Designed using anthracycline and distamycin-based scaffolds to create small molecule agents binding extended DNA sequences. • A highly potent cytotoxic agent (picomolar-level IC 50 ) against brain tumor cell lines; hundreds-fold greater than the classical DNA binders like daunorubicin or doxorubicin. • In vivo testing demonstrated high uptake of WP1244 in the brain and subsequently antitumor activity in orthotopic models of brain cancer. • In May 2020, the Company entered into a Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center related to WP1244. A DNA-BINDING AGENT REPRESENTING A NOVEL CLASS OF POTENTIAL THERAPEUTICS.